Grethe Jakobsen

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Kristine B. Degn, Claus Bogh Juhl, Jeppe Sturis et al. · Diabetes · 2004 · 424 citations · Full text

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)

Sten Madsbad, Ole Schmitz, Jonas Ranstam et al. · Diabetes Care · 2004 · 309 citations · Full text

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

B. Elbrønd, Grethe Jakobsen, Søren Erik Larsen et al. · Diabetes Care · 2002 · 282 citations · Full text

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Claus Bogh Juhl, Malene Hollingdal, Jeppe Sturis et al. · Diabetes · 2002 · 266 citations · Full text

The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose

Annette M. Chang, Grethe Jakobsen, Jeppe Sturis et al. · Diabetes · 2003 · 208 citations · Full text